Plerixafor Plus Donor Lymphocyte Infusion for Relapsed Acute Leukemia After Allo-HSCT

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

January 31, 2025

Study Completion Date

July 31, 2025

Conditions

Relapsed Adult ALLRelapsed Adult AML

Interventions

DRUG

Plerixafor

Plerixafor was injected subcutaneously to participants twice per day for five consecutive days ten days post DLI.

Trial Locations (1)

First Hospital of Jilin University, Changchun

All Listed Sponsors

lead

The First Hospital of Jilin University

OTHER

NCT06141304 - Plerixafor Plus Donor Lymphocyte Infusion for Relapsed Acute Leukemia After Allo-HSCT | Biotech Hunter | Biotech Hunter